Summary
1. The metabolic fate of intravenous and oral propranolol has been studied after single doses in man using 14C labelled propranolol. — 2. After oral administration there is virtually complete absorption and peak blood levels of propranolol and 4-hydroxy propranolol (a beta blocking metabolite) are seen at about 1 1/4 h after administration. Studies in normal subjects confirm that the maximum degree of beta blockade occurs at this time. — 3. Following intravenous administration, no 4-hydroxy propranolol is seen and the possible reasons for this are discussed. — 4. Excretion of the administered radio-active dose is mainly in the urine, with only 1%–4% of the administered radio-activity appearing in the faeces after both intravenous and oral dosing. — 5. The major metabolite so far identified in the urine is naphthoxylactic acid, which accounts for approximately 20% and 40% of oral and i.v. doses respectively. — 6. The greater proportion of radio-activity excreted in the urine (30–60% of the administered dose) is as yet unidentified although it may be a conjugate of propranolol. The level of total blood radio-activity following both intravenous and oral propranolol is very much higher than that of either propranolol or 4-hydroxy propranolol. The major portion of this blood radio-activity appears to be the same as the unidentified urinary metabolite. — 7. Following intravenous doses the decline of pharmacological response roughly parallels that of propranolol concentration in the plasma, and does not correlate with the plasma concentration of the unidentified metabolite.
Similar content being viewed by others
References
Barrett, A.M.: Personal Communication
— Management of coronary artery disease. Brit. med. J. 1969 I, 318–319.
Bond, P.A.: Metabolism of propranolol (Inderal), a potent specific β-adrenergic receptor blocking agent. Nature 213, 721 (1967).
Chamberlain, D. A.: The haemodynamic effects of beta adrenergic blockade in man. Cardiologia 49, Suppl. 2, 27–42 (1966).
Cooper, R. G., Hayes, A.: Personal Communication.
Gillam, P. M. S., Prichard, B. N. C.: Propranolol in the therapy of angina pectoris. Amer. J. Cardiol. 18, 366–369 (1966).
Grant, R. H. E., Keelan, P., Karnohan, R. J., Leonard, J. C., Nancepievill, L., Sinclair, K.: Multicenter trial of propranolol in angina pectoris. Amer. J. Cardiol. 18, 361–369 (1966).
Hayes, A., Cooper, R. G.: Studies on the absorption, distribution and excretion of propranolol in various species. Pharm. Exp. Ther. (In press).
Kalberer, F., Rutschmann, J.: Oxygen flask combustion of tissues containing 14C, 35S and 3H. Helv. chim. Acta 44, 1956–1966 (1961).
Management of coronary artery disease. Leading article. Brit. med. J. 1969 I, 37–38.
Prichard, B.N.C., Gillam, P.M.S.: Propranolol in hypertension. Amer. J. Cardiol. 18, 381–391 (1966).
—— Treatment of hypertension with propranolol. Brit. med. J. 1969 I, 7–16.
Wolfson, S., Gorlin, R.: Physiological and clinical aspects of beta adrenergic blockade. Ann. N.Y. Acad. Sci. 139, 1003–1009 (1967).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
PAterson, J.W., Conolly, M.E., Dollery, C.T. et al. The pharmacodynamics and metabolism of propranolol in man. Pharmacol. Clin. 2, 127–133 (1970). https://doi.org/10.1007/BF00420338
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00420338